Intercept Pharmaceuticals, Inc. ICPT
We take great care to ensure that the data presented and summarized in this overview for INTERCEPT PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ICPT
View allLatest Institutional Activity in ICPT
Top Purchases
Top Sells
About ICPT
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Insider Transactions at ICPT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 08
2023
|
Srinivas Akkaraju Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,111
-100.0%
|
$154,109
$19.0 P/Share
|
|
Nov 08
2023
|
Srinivas Akkaraju Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
640,688
-100.0%
|
$12,173,072
$19.0 P/Share
|
|
Nov 08
2023
|
Srinivas Akkaraju Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
37,887
-100.0%
|
$719,853
$19.0 P/Share
|
|
Nov 08
2023
|
Nancy Miller Rich Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,111
-100.0%
|
$154,109
$19.0 P/Share
|
|
Nov 08
2023
|
Nancy Miller Rich Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,304
-100.0%
|
$423,776
$19.0 P/Share
|
|
Nov 08
2023
|
Gino Santini Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,111
-100.0%
|
$154,109
$19.0 P/Share
|
|
Nov 08
2023
|
Gino Santini Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
23,645
-100.0%
|
$449,255
$19.0 P/Share
|
|
Nov 08
2023
|
Glenn Sblendorio Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,111
-100.0%
|
$154,109
$19.0 P/Share
|
|
Nov 08
2023
|
Glenn Sblendorio Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
23,447
-100.0%
|
$445,493
$19.0 P/Share
|
|
Nov 08
2023
|
Luca Benatti Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,111
-100.0%
|
$154,109
$19.0 P/Share
|
|
Nov 08
2023
|
Luca Benatti Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
25,487
-100.0%
|
$484,253
$19.0 P/Share
|
|
Nov 08
2023
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
26,585
-100.0%
|
$505,115
$19.0 P/Share
|
|
Nov 08
2023
|
Linda M Richardson EVP & Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,706
-100.0%
|
$317,414
$19.0 P/Share
|
|
Nov 08
2023
|
Fundaro Paolo Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,111
-100.0%
|
$154,109
$19.0 P/Share
|
|
Nov 08
2023
|
Fundaro Paolo Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
35,794
-100.0%
|
$680,086
$19.0 P/Share
|
|
Nov 08
2023
|
M Michelle Berrey President, R&D and CMO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
51,790
-100.0%
|
$984,010
$19.0 P/Share
|
|
Nov 08
2023
|
M Michelle Berrey President, R&D and CMO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
28,349
-100.0%
|
$538,631
$19.0 P/Share
|
|
Nov 08
2023
|
Rocco Venezia Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,669
-100.0%
|
$278,711
$19.0 P/Share
|
|
Nov 08
2023
|
Rocco Venezia Chief Accounting Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,782
-100.0%
|
$204,858
$19.0 P/Share
|
|
Nov 08
2023
|
Andrew Saik EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
45,244
-100.0%
|
$859,636
$19.0 P/Share
|